PROCEPT BioRobotics Q3 revenue $20.3M (+135% YoY), raises 2022 guidance to ~$72.5M

PROCEPT BioRobotics Corp

2022-Q3 EPS reported -$1.33 revenue$51,237,000

Total revenue $20.3M, +135% YoY; US system rev $9.8M (+95%), handpiece $8.0M (+267%).
Net loss $22.6M vs $14.1M prior year; Adjusted EBITDA loss $18.3M.
FY2022 revenue guidance raised to ~$72.5M (110% growth) from $66-68M; gross margin 50-51%.
New $52M five-year loan on Oct 10 retired $50M facility; reduces annual interest ~$2.8M.
Multi-system national contract with Providence for AquaBeam Robotic Systems announced Sept 19.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PROCEPT BioRobotics Corp reported for the quarter ended September 30, 2022 results: revenue $20.3 million. Guidance raised.

Period: for the quarter ended September 30, 2022
Revenue: $20.3 million
Guidance: raised
Result: reported results

Exact text from the filing

care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2022. Recent Highlights • Total Revenue of $20.3 million for the third quarter of 2022, an increase of 135% compared to the prior year period • U.S. system and rental revenue of $9.8 million for the third quarter of 2022, an increase

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

PROCEPT BioRobotics Corp filing history →

Source: SEC EDGAR

accession 0001588978-22-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.